The antiandrogenic therapy (ADT) for prostate cancer represents an additional risk factor for the development of osteoporosis and fragility fractures.
Still, bone health of patients on ADT is often not evaluated. After literature research we found that simple preventive measures can prevent bone loss in these patients, resulting in more cost-effective solutions to the public health system and family when compared to the treatment of fractures.
Cançado BL, Miranda LC, Madeira M, Farias ML. Are you the author?
Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Departament of Endocrinology, Faculty of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Reference: Rev Col Bras Cir. 2015 Jan-Feb;42(1):62-6.